期刊文献+

进展期胃癌术后三维适形放疗联合同期XELOX化疗临床观察 被引量:3

下载PDF
导出
摘要 目的研究进展期胃癌术后三维适形放疗联合同期化疗的临床效果。方法进展期胃癌根治术后患者160例,随机分为对照组和观察组,每组80例,对照组接受XELOX方案,全部患者接受2~3周期化疗;观察组在对照组的基础上实施三维适形放疗,PTV边缘的处方剂量为50Gy。结果观察组近期疗效优于对照组(P<0.05)。2组白细胞分级比较差异无统计学意义(P>0.05)。观察组发生急性放射反应3例,能够耐受。结论进展期胃癌术后实施三维适形放疗联合同期XELOX方案化疗与常规化疗相比,提高近期疗效完全缓解+部分缓解率,急性毒副反应可以耐受,可以推荐临床应用。
出处 《河北医药》 CAS 2011年第6期860-861,共2页 Hebei Medical Journal
  • 相关文献

参考文献2

二级参考文献18

  • 1Cheng-WuZhang,Shou-ChunZou,DunShi,Da-JianZhao,Cheng-WuZhang.Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer[J].World Journal of Gastroenterology,2004,10(20):3070-3072. 被引量:30
  • 2朱正纲.术前区域性辅助化疗对改善胃癌手术疗效的临床意义[J].中国实用外科杂志,2005,25(7):389-391. 被引量:16
  • 3Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:429
  • 4Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperativeirradiation and surgery in the treatment of adenoearcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys, 1998,42:929-934.
  • 5Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med,2001,345 :725- 730.
  • 6Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol, 2002,12 : 187-195.
  • 7Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys,2002,52:283-293.
  • 8Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med,2001,345 :725-730.
  • 9Leong T, Willis D, Joon DL, et al. 3D conformal radiotherapy for gastric cancer-resuhs of a comparative planning study. Radiat Oncol, 2005,74:301-306.
  • 10van't Riet A, Mak AC, Moerland MA, et al. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys, 1997,37 : 731-736.

共引文献45

同被引文献41

  • 1王树森,管忠震,向燕群,汪波,林桐榆,姜文奇,张力,张惠忠,侯景辉.鼻咽癌组织中EGFR和p-ERK蛋白表达的检测及意义[J].中华肿瘤杂志,2006,28(1):28-31. 被引量:46
  • 2黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 3胡巧英,刘鹏,王磊,付真富.Ⅲ、Ⅳ a期鼻咽癌患者放疗同期化疗加辅助化疗的疗效[J].癌症,2007,26(4):394-397. 被引量:43
  • 4Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks lig and binding while permitting the active receptor conformation. Cancer Res,2009,69 (14) :5851-5859.
  • 5Loeffler-Ragg J, Schwentner I, Sprinzl GM, et al. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs,2008,17 (10) : 1517-1531.
  • 6Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Mabs ,2009,1 ( 1 ) :41-45.
  • 7Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer,2009,100(6) :950-958.
  • 8Rojo F, Gracias E, Villena N, et al. Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck:A SENDO Foundation Study. Clin Cancer Res, 2010,16 (8) :2474-2482.
  • 9Rodriguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther,2010,9(5 ) :343-349.
  • 10蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M]4版.北京:中国协和医科大学出版社,2008:309-311.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部